Overview

Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)

Status:
Active, not recruiting

Trial end date:
2022-05-28

Target enrollment:

Participant gender:

Summary

This is a study of pembrolizumab (MK-3475) versus standard of care (SOC) treatment (capecitabine, gemcitabine, or docetaxel) for the treatment of recurrent or metastatic nasopharyngeal cancer (NPC). Participants will be randomly assigned to receive either pembrolizumab or Investigator's choice of SOC treatment. The primary study hypothesis is that pembrolizumab treatment prolongs Overall Survival (OS) when compared to SOC treatment.

Phase:

Phase 3

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Capecitabine
Docetaxel
Gemcitabine
Pembrolizumab